---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-26-000090"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2026-05-22T20:50:14+00:00"
generated_at: "2026-05-22T20:52:23.219999+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics 2026 annual meeting results: directors elected, auditor ratified

## Summary
- Elected three Class III directors to serve until 2029: Akkaraju (67.1M for), Slingsby (67.1M for), Karydas (66.6M for).
- Ratified Ernst & Young as independent auditor for fiscal year 2026 with 72.6M votes for, 9.5K against.
- Broker non-votes of 5.6M shares on director election proposals; no non-votes on auditor ratification.
- All proposals passed with requisite affirmative votes as described in the April 8, 2026 proxy statement.

## SEC filing metadata
- accession: 0001933414-26-000090
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2026-05-22T20:50:14+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000090/0001933414-26-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341426000090/mlys-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-26-000090
- JSON: https://secwatch.observer/filing/0001933414-26-000090.json
- Plain text: https://secwatch.observer/filing/0001933414-26-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.